Get started
Author

Haoqian Xu

Observed name: H. Xu
ORCID: 0009-0004-3588-5651
Observed ORCID: 0009-0004-3588-5651
OpenAlex ID: A5025355489
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
2024 · Yufeng Zhang, Haiyan Zhang, et al. · World Journal of Surgical Oncology · 13
Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer
2023 · Jiabing Wang, Haoqian Xu, et al. · Canadian Journal of Gastroenterology and Hepatology · 12
PDF
2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
2022 · S. Lu, J. Fang, et al. · Annals of Oncology · 11
Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection
2023 · Yanyan Ye, Ying Wang, et al. · BMC Gastroenterology · 9
PDF
Comparison of Different First‐Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta‐Analysis
2022 · Long Feng, Ying Wang, et al. · BioMed Research International · 7
PDF
Works count: 5
Citation count: 52
H-index: 5
I10-index: 3
Year
Topic
Type